Clinical trials: SBRT
Solid Tumor Spine Metastases
Radiotherapy for Solid Tumor Spine Metastases
Although it is being increasingly used off protocol, there is minimal data regarding the efficacy of stereotactic radiosurgery to the tumor bed following surgical resection of metastatic lesions to the spine.
- Trial name
- NCT01752036
- Testing
- Post-operative, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Trial name
- NCT00891904
- Testing
- cetuximab, stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Lung Cancer, Stage IV Lung Cancer
Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer
This phase III trial studies immunotherapy and stereotactic body radiation therapy to see how well it works compared with immunotherapy alone after first-line systemic therapy (therapy that goes throughout the body) in treating…
- Trial name
- NCT03867175
- Testing
- Stereotactic Body Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Cancer
Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma
OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible.
- Trial name
- NCT00983541
- Testing
- Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Hepatocellular Carcinoma (HCC)
Y90 Radiation Segmentectomy vs SBRT for HCC
The proposed study is a single site, prospective, randomized pilot study to assess the feasibility of recruitment of patients into a trial evaluating the efficacy and tolerability of selective transarterial Y90 radioembolization…
- Trial name
- SBRT vs Y90 (NCT04235660)
- Testing
- Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Indiana University
Pancreatic Cancer
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and SBRT (focused radiation) is effective (anti-tumor…
- Trial name
- NCT02648282
- Testing
- Cyclophosphamide, GVAX Pancreatic Cancer Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Stereotactic Body Radiotherapy for Prostate Cancer
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.
- Trial name
- NCT01352598
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mercy Research
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
This phase II trial studies the effect of standard of care chemotherapy with or with out stereotactic body radiation therapy in treating patients with pancreatic cancer that has spread to a limited amount of places in the body…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04975516
- Testing
- Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer, Stereotactic Body Radiation Therapy
Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or placebo to patients who have been diagnosed with…
- Trial name
- NCT03340974
- Testing
- GC4419, Stereotactic Radiation Therapy (SBRT) 50 Gy, Stereotactic Radiation Therapy (SBRT) 55 Gy
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- Galera Therapeutics, Inc.
Adenocarcinoma of the Pancreas
SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma
The current study seeks to further investigate the impact of Stereotactic Body Radiation Therapy following pancreatic resection with a close or positive margin.
- Trial name
- NCT01357525
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- David A. Clump, MD, PhD
Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
The purpose of this study is to test the effects, of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in subjects with inoperable, recurrent, or progressive squamous cell carcinoma of the head and…
- Trial name
- NCT04685499
- Testing
- OBP-301, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Stage IV Adult Soft Tissue Sarcoma, Sarcoma,Soft Tissue
(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
This is a prospective study to document the local control rates with SBRT specifically for pulmonary metastases from soft tissue sarcoma.
- Trial name
- NCT01949506
- Testing
- SBRT
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical College of Wisconsin
Oligometastatic Disease
Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation
This study will evaluate the feasibility of radiosurgery for all metastatic sites in patients presenting with oligometastatic disease, defined here as 5 or fewer sites of metastatic disease involving 3 or fewer organ systems.
- Trial name
- NCT01345539
- Testing
- Stereotactic Radiosurgery (SRS), Chemotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Steven Burton
Stage II Prostate Adenocarcinoma AJCC v7
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer
This randomized phase III trial studies how well stereotactic body radiation therapy works compared to intensity-modulated radiation therapy in treating patients with stage IIA-B prostate cancer.
- Trial name
- NCT03367702
- Testing
- Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 293 sites in United States, Canada and 4 more
- Volunteers
- 698 people
- Sponsor
- NRG Oncology
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Carcinoma, Renal Cell
Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma
The specific aims of this study are: 1. To determine the safety and feasibility of treating patients with a combination of MRI guided stereotactic body radiation therapy and microwave ablation. 2.
- Trial name
- NCT02782715
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Microwave Ablation (MWA)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Pancreatic Cancer
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC.
- Trial name
- NCT03599362
- Testing
- Nivolumab + Cabiralizumab, Stereotactic Body Radiotherapy (SBRT)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- NYU Langone Health
Pancreatic Cancer
Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas
The purpose of this study is to estimate safety of GVAX Pancreas Vaccine (GVAX) with immune modulating doses of cyclophosphamide (Cy) followed by SBRT and FOLFIRINOX chemotherapy in pancreatic cancer patients after surgery.
- Trial name
- NCT01595321
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine, Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SBRT, Borderline Resectable Pancreatic Cancer
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline…
- Conditions
- SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT04698915
- Testing
- Drug GC4711
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 177 people
- Sponsor
- Galera Therapeutics, Inc.
Newly Diagnosed Oligometastatic Prostate Cancer
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy…
- Trial name
- NCT03298087
- Testing
- radical prostatectomy, stereotactic body radiotherapy, Leuprolide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development